BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from ...

Concepts Inc (NASDAQ:TMCI) received an upgrade from BTIG, with analyst Ryan Zimmerman changing the stock rating from Neutral to Buy and setting a new price target of $16.00. This upgrade comes after a ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical Concepts (TMCI – Research Report) to a Buy today and set a price target of $16.00. The ...

Treace Medical Concepts, Inc.’s TMCI share price has surged by 10.21%, which has investors questioning if this is right time to sell.

PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and ...

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in ...

Treace Medical Concepts, Inc. TMCI recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure.

Detailed price information for Treace Medical Concepts Inc (TMCI-Q) from The Globe and Mail including charting and trades.

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...